Remsima® (infliximab) has been approved and listed on the PBS as the first subcutaneous (SC) biosimilar formulation of infliximab from the 1st of July 2021. This marks a significant development in the history of infliximab, which was first approved as an intravenous (IV) infusion over 20 years ago.1-4 In that time, infliximab has become a ...
Subcutaneous infliximab a welcome treatment alternative for patients with inflammatory bowel disease.
3 Aug 2021
Sponsored by Celltrion Healthcare Australia Pty Ltd